## Supplementary data

# Norsampsone E, an unprecedented decarbonyl polycyclic polyprenylated acylphloroglucinols with homoadamantyl core from *Hypericum sampsonii*

Wen-Jing Tian,<sup>a</sup> Yu-Qin Qiu,<sup>b</sup> Jun-Jie Chen,<sup>a</sup> Xiao-Jun Yao,<sup>c</sup> Guang-hui Wang, <sup>a</sup> Yi

Dai, \*b Hai-Feng Chen, \*a and Xin-Sheng Yao\*b

<sup>a</sup> Fujian Provincial Key Laboratory of Innovative Drug Target Research, School of Pharmaceutical Sciences, Xiamen University, Xiamen 361005, P. R. China.

<sup>b</sup> Institute of Traditional Chinese Medicine & Natural Products, Jinan University, Guangzhou 510632, P. R. China.

<sup>c</sup> State Key Laboratory of Quality Research in Chinese Medicine, Macau Institute for Applied Research in Medicine and Health, Macau University of Science and Technology, Taipa, Macau, P. R. China.

\* Corresponding author: Tel: +86 20 85220785; fax: +86 20 8522 1559

\* E-mail address: daiyi1004@163.com; haifeng@xmu.edu.cn; tyaoxs@jnu.edu.cn

## List of Supporting Information

1. Spectral information of <b>1</b>		
1.1. UV, IR (KBr disc) and HR-ESI-MS spectrum of 1 in CH <sub>3</sub> OH		3
1.2. 1D and 2D NMR spectra of 1 in CDCl <sub>3</sub>		4-6
1.2.1	<sup>1</sup> H NMR spectrum of <b>1</b> in CDCl <sub>3</sub>	4
1.2.2	<sup>13</sup> C NMR spectrum of <b>1</b> in CDCl <sub>3</sub>	4
1.2.3	HSQC spectrum of 1 in CDCl <sub>3</sub>	5
1.2.4	<sup>1</sup> H- <sup>1</sup> H COSY spectrum of <b>1</b> in CDCl <sub>3</sub>	5
1.2.5	HMBC spectrum of 1 in CDCl <sub>3</sub>	6
1.2.6	NOESY spectrum of 1 in CDCl <sub>3</sub>	6
2. Spectral information of <b>2</b>		
2.1. UV, IR (KBr disc) and HR-ESI-MS spectrum of 2 in CH <sub>3</sub> OH		7
2.2. 1D and 2D NMR spectra of 2 in CDCl <sub>3</sub>		
2.2.1	<sup>1</sup> H NMR spectrum of <b>2</b> in CDCl <sub>3</sub>	8
2.2.2	<sup>13</sup> C NMR spectrum of <b>2</b> in CDCl <sub>3</sub>	8
2.2.3	HSQC spectrum of <b>2</b> in CDCl <sub>3</sub>	9
2.2.4	<sup>1</sup> H <sup>-1</sup> H COSY spectrum of <b>2</b> in CDCl <sub>3</sub>	9
2.2.5	HMBC spectrum of <b>2</b> in CDCl <sub>3</sub>	10
2.2.6	NOESY spectrum of 2 in CDCl <sub>3</sub>	10
3. Bioassay	′S	
3.1. SPR-based biacore assays		11
3.2. RXRα transcriptional activities		
4 Reference	e	

## UV spectrum of Norsampsone E (1) in CH<sub>3</sub>OH.



## IR (KBr disc) spectrum of Norsampsone E (1).



### HR-ESI-MS spectrum of Norsampsone E (1).

Single Mass Analysis Tolerance = 5.0 mDa / DBE: min = -1.5, max = 50.0 Element prediction: Off Number of isotope peaks used for i-FIT = 3 Monoisotopic Mass, Even Electron Ions 112 formula(e) evaluated with 1 results within limits (up to 20 best isotopic matches for each mass) Elements Used: C: 0-500 H: 0-1000 O: 0-200 HS2A2D14-5 2015011204 275 (2.214) 1: TOF MS ES+ 1.61e+004 455.3161 100 % 456.3193 601.3528 471.3108 602.3582 975.6602 1023.6878 1123.6814 m/z 319.1910 365.2314 687.4461 785.5499 124.0890 209.1537 1 700 800 900 1000 400 1100 500 600 300 Minimum: -1.5 5.0 10.0 50.0 Maximum: Calc. Mass 455.3161 mDa 0.0 i-FIT Norm 87.4 n/a Conf (%) Formula n/a C29 H43 04 Mass 455.3161 PPM DRF 0.0 8.5



<sup>13</sup>C NMR spectrum (AV-400, 100 MHz) of Norsampsone E (1) in CDCl<sub>3</sub>





HSQC spectrum (AV-400) of Norsampsone E (1) in CDCl<sub>3</sub>

<sup>1</sup>H-<sup>1</sup>H COSY spectrum (AV-400) of Norsampsone E (1) in CDCl<sub>3</sub>





HMBC spectrum (AV-400) of Norsampsone E (1) in CDCl<sub>3</sub>

NOESY spectrum (AV-400) of Norsampsone E (1) in CDCl<sub>3</sub>



UV spectrum of hypersampsone X (2) in CH<sub>3</sub>OH.



IR (KBr disc) spectrum of hypersampsone X (2).





#### Single Mass Analysis Tolerance = 5.0 mDa / DBE: min = -1.5, max = 50.0 Element prediction: Off Number of isotope peaks used for i-FIT = 3 Monoisotopic Mass, Even Electron Ions 677 formula(e) evaluated with 4 results within limits (up to 20 best isotopic matches for each mass) Elements Used: C: 0-500 H: 0-1000 O: 0-200 Na: 0-1 Br: 0-8 2015011206 266 (2.147) 1: TOF MS ES+ 2.72e+004 501.3016 100 % 502.3040 312.3639 517.2957 483.2897 284.332 589.4292 677.4810 799.6669 851.7082 00 700 800 900 1018.6227 1062.6210 1143.6539 1000 1100 1200 124.0879 0-100 200 400 600 300 500 Minimum: Maximum: -1.5 50.0 5.0 10.0 mDa 3.5 -4.8 1.1 -2.4 Calc. Mass 501.2981 501.3064 501.3005 501.3040 PPM 7.0 -9.6 2.2 -4.8 DBE 10.5 4.5 13.5 1.5 i-FIT 137.4 137.9 138.5 139.3 Conf (%) Formula 46.66 C31 H42 04 Na 29.71 C26 H45 09 16.65 C33 H41 04 6.98 C24 H46 09 Na Norm 0. 762 1. 214 1. 793 2. 663 Mass 501.3016



<sup>13</sup>C NMR spectrum (AV-600, 150 MHz) of hypersampsone X (2) in CDCl<sub>3</sub>





<sup>1</sup>H-<sup>1</sup>H COSY spectrum (AV-600) of hypersampsone X (2) in CDCl<sub>3</sub>



HSQC spectrum (AV-600) of hypersampsone X (2) in CDCl<sub>3</sub>



HMBC spectrum (AV-600) of hypersampsone X (2) in CDCl<sub>3</sub>

NOESY spectrum (AV-600) of hypersampsone X (2) in CDCl<sub>3</sub>



## Bioassays

### **Biacore assay**

**RXRa-LBD protein purified.** The 0.79 kb DNA fragment corresponding to the ligand-binding domain (LBD) of human RXR $\alpha$  (genes 592-1386) was excised from MCF-7 cells and sub-cloned into pET-15b between the BamHI and NheI restriction site. Transformed E. coli BL<sub>21</sub>(DE3) were grown at 37°C in LB medium until OD<sub>600</sub> = 0.6-0.8, Protein expression was initiated by 0.4 mM IPTG, and this procedure sustained at 18 °C for 16 h. Following centrifugation, resuspension and sonication processes, the combinated protein was purificated by Ni<sup>2+</sup>-NTA agarose column at low temperatures.

**SPR assay.** The measurements were performed on the Biacore T200 (Biacore GE) at 25 °C in a running buffer comprising PBS (pH 7.5), 150 mM NaCl, 10 mM MgCl<sub>2</sub> and 0.1% P20. CM5 chips (Biacore GE) were first treated with EDC-NHS mixture at a flow rate of 10 ml/min. Purified RXR $\alpha$ -LBD protein was immobilized on the sensor chip by the standard amine coupling protocol with resonance unit around 8000 RU. All test samples were dissolved in dimethyl sulfoxide (DMSO) to make stock solutions and further diluted in PBS. Gradient concentrations of each compound (100  $\mu$ M, 50  $\mu$ M, 25  $\mu$ M, 12.5  $\mu$ M, 6.25  $\mu$ M, 3.125  $\mu$ M) were injected through flow cells immobilized with purified RXR $\alpha$ -LBD protein. The chip is being exposed to ligand solution during 0–120 s, and the ligand is dissociated from the chip by running buffer from 120 to 420 s. The K<sub>D</sub> values were calculated from the experimental curve with Biacore T200 evaluation software package. The formation of surface-bound complexes was analyzed according to the interaction type of A+B $\leftrightarrow$ AB.



Figure 1. SPR results of compound 1-2 binding to RXRa-LBD.

## RXR*α* transcriptional activity assay

**Cell Culture**. The human renal epithelial cells (293T) (ATCC) were cultured in 37 °C in DMEM (Hyclone) containing 10% fetal bovine serum (FBS, Hyclone) for 24 h. **Experimental Methods**. The previous dual-luciferase reporter gene assay with some modification was used in the present study <sup>1, 2</sup>. In brief, approximately  $1.5 \times 10^4$  cells / well were seeded in 96-well plates. The two target plasmids, 20 ng pBind RXR $\alpha$  LBD (provided by Dr. Xiao-kun Zhang from the Burnham Institute for Medical Research, Cancer Center, La Jolla, CA, USA.) and 50 ng PG5 LUC (provided by Dr. Xiao-kun Zhang from the Burnham Institute for Center, La Jolla, CA, USA.), were transfected by Liposome 2000 (Invitrogen) in the cell. After 24 h, the cells were exposed to the test compound for 12 h. Then the cells were rinsed with PBS and lysed by buffered solution (1 × PLB) on the oscillating platform for 15 minutes. According to the introduction of the Dual-Luciferase Reporter Assay System kit (promega), the activities of Firefly luciferase (FL) and Rellina luciferase (RL) were checked.

Relative luciferase activity (%) =  $FL / RL \times 100\%$ 



Figure 2. Effects of compounds 1-2 (5, 10, and  $20\mu$ M) on the transcriptional activities of RXR $\alpha$ 

## Reference

(1) Zhang, X. K.; Lehmann, J.; Hoffmann, B.; Dawson, M. I.; Cameron, J.; Graupner, G.; Hermann, T.; Tran, P.; Pfahl, M. *Nature* **1992**, *358*, 587–591.

(2) Duan, Y. H.; Dai, Y.; Wang, G. H.; Zhang, X.; Chen, H. F.; Chen, J. B.; Yao, X. S.; Zhang, X. K. *J. Nat. Prod.* **2010**, 73, 1283-1287.